BMO Increases DexCom Price Target From $68 To $78 And Reiterates Their Outperform Rating As Co. Received G6 CGM FDA Approval Ahead Of Schedule; Believes Approval Gives Co. Momentum And Awaits An Update On Product Pricing, Guidance On Q1 Earnings Call
Eddie Staley